|Bid||163.00 x 800|
|Ask||164.98 x 900|
|Day's Range||163.00 - 172.50|
|52 Week Range||96.42 - 174.50|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||172.11|
GW Pharmaceuticals (NASDAQ:GWPH) shares were surging on Wednesday as the U.S. Drug and Enforcement Administration (DEA) has plans to reclassify one of its medications. The company’s shares were on the rise, while trading volume was also soaring by more than four times the company’s daily average following a report from Morgan Stanley’s David Lebowitz. The report claimed that the agency has plans to reclassify the company’s Epidiolex (cannabidiol), which will now be allowed for medicinal use.
Shares of several popular Canadian marijuana producers--including Tilray (TLRY), Canopy Growth (CGC), and Cronos Group (CRON)--were surging once again on Wednesday as Wall Street grows ever-more bullish on the prospects of legalization and U.S. imports.
HENDERSON, NV / ACCESSWIRE / September 19, 2018 / It's just a matter of time before medical marijuana will become legal in all 50 states. It's not surprising when you consider a recent poll shows 93% of ...
Morgan Stanley expects the DEA to drop Epidiolex from Schedule I — the same level as cocaine, heroin and other illegal substances — to Schedule IV, where Xanax, Ambien and Tramadol rank. At worst, it would fall to Schedule III alongside moderately to lowly addictive drugs like codeine and anabolic steroids, Lebowitz said.
NEW YORK, NY / ACCESSWIRE / September 19, 2018 / U.S. markets closed up Tuesday on the strength of upbeat corporate earnings and strong economic data. On Tuesday, China announced tariffs of between 5 to ...
Tilray CEO Brendan Kennedy told CNBC that pharmaceutical companies must start thinking about partnering with cannabis producers as a "hedge" against the space.
SAN DIEGO (AP) — In a rare move, the U.S. government has approved the importation of marijuana extracts from Canada for a clinical trial, highlighting a new avenue for American researchers who have long had trouble obtaining the drug for medical studies.
HENDERSON, NV / ACCESSWIRE / September 13, 2018 / CBD stocks have been lining the pockets of their investors for years now. Unfortunately, many of them have been doing so well it can be argued that a majority ...
Though this pot stock has been unstoppable for years, things may not stay that way for much longer.
Marijuana stocks, fueled by what may well be the biggest legal and medical revolution in years, have already proven they’re blazing their own trail. In all cases, though, there’s explosive potential on the table — the legal marijuana industry’s story has just gotten that compelling, as more states seek to legalize it while regulators finally start to see its legitimate medical benefits. Of all the marijuana stocks worth a look right now, Canopy Growth (NYSE:CGC) has garnered the most attention of late.
Surging investor appetite for pot stocks has led one cannabis-focused exchange-traded fund (ETF) to break the billion-dollar mark for the first time. In a press release, The Horizons Marijuana Life Sciences Index ETF ( HMMJ), which offers direct exposure to North American-listed companies with business activities in the marijuana industry, said its total assets under management have grown to more than $1 billion Canadian dollars — $760 million U.S. dollars at the current exchange rate. The ETF’s shares have surged 43% in the past month, according to CNBC, and 124% since it debuted on the Toronto Stock Exchange in April 2017 as investor enthusiasm for its top holdings continues to soar.
Hypothetically speaking, the federal government could be in a lose-lose situation if it legalizes recreational cannabis.
HENDERSON, NV / ACCESSWIRE / September 4, 2018 / Very interesting Hemp, and CBD firm that we have discovered is CIIX. CIIX it appears is positioning itself to become China's GW Pharma (NASDAQ: GWPH). Just ...